According to a recent LinkedIn post from Strive Health, the company is marking the six‑year anniversary of its first patient visit. The post traces the evolution from a small number of initial encounters to what is described as thousands of weekly visits for people with kidney disease and other chronic conditions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights its “Kidney Heroes®” and broader staff as central to this growth, emphasizing a “Patients First” ethos and positioning Strive’s care model as redefining specialty care. For investors, this sustained volume expansion may indicate increasing penetration in value‑based kidney care and a more entrenched position in chronic‑care management.
As shared in the post, Strive frames each visit as evidence of organizational commitment to patient‑centric care, suggesting a service‑intensive model with potentially high engagement per patient. If visit growth is matched by efficient reimbursement structures and strong payer or provider partnerships, this scale could support recurring revenue streams and strengthen the company’s competitive moat in kidney‑focused specialty care.
The focus on chronic conditions beyond kidney disease hints at a possible broadening of Strive’s addressable market within complex‑care populations. For the wider industry, the post underscores ongoing momentum behind specialized, value‑based care platforms that target high‑cost, high‑acuity patients, a segment that continues to draw interest from payers and private equity investors.

